Form 4: Immunome Director Jean Jacques Bienaime Reports Transaction in Company Stock
SEC Form 4 Filing
Director Jean Jacques Bienaime reported the acquisition of 2,000 shares of Immunome Inc. common stock on May 21, 2024.
Summary
- On May 21, 2024, Jean Jacques Bienaime, a director of Immunome Inc., purchased 2,000 shares of common stock at a price of $13.5699 per share.
- Following this transaction, Bienaime directly owns 9,615 shares of Immunome Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a small transaction.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company insiders, such as directors and officers, regarding their holdings of the company's securities.
Stakeholder Impact
- The purchase could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/21/2024 | Date of transaction: Jean Jacques Bienaime purchased 2,000 shares of Immunome Inc. common stock. |
| 05/22/2024 | Date of signature: Sandra Stoneman, Attorney-in-Fact, signed the Form 4 on behalf of Jean Jacques Bienaime. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.